Advagraf®, a once‐daily prolonged release tacrolimus formulation,in kidney transplantation: literature review and guidelines from a panel of experts |
| |
| Authors: | Sophie Caillard Bruno Moulin Fanny Buron Christophe Mariat Vincent Audard Philippe Grimbert Pierre Marquet |
| |
| Affiliation: | 1. Nephrology and Transplant Department, Strasbourg University Hospital, Strasbourg, France;2. Transplant, Nephrology and Immunology Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France;3. Nephrology, Dialysis and Renal Transplants Department, North Hospital, Saint Etienne University Hospital, Saint Priest en Jarez, France;4. Nephrology and Transplant Department, Institut Francilien de Recherche en Néphrologie et Transplantation (IFRNT), Assistance Publique H?pitaux de Paris, Henri‐Mondor Hospital, Créteil, France;5. CHU Limoges, UMR 850 INSERM, University of Limoges, Limoges, France |
| |
| Abstract: | The efficacy and safety of tacrolimus twice‐a‐day (BID) and once‐a‐day (QD) formulations are similar. However, the available information regarding the initiation and management of tacrolimus QD is sparse and practical information is lacking. A panel of French experts extensively reviewed the available literature on tacrolimus pharmacokinetics, clinical efficacy, and safety in kidney transplantation and, based on their own day‐to‐day experience, provided the practitioners with practical guidelines for the daily use and management of tacrolimus QD in de novo initiation or early conversion. |
| |
| Keywords: | clinical practice extended release tacrolimus immunosuppression kidney transplant therapeutic drug monitoring |
|
|
